Lynx1 Capital Management Lp Top Holdings and 13F Report (2025) About Lynx1 Capital Management LpInvestment ActivityLynx1 Capital Management Lp has $266.71 million in total holdings as of December 31, 2024.Lynx1 Capital Management Lp owns shares of 18 different stocks, but just 6 companies or ETFs make up 80% of its holdings.Approximately 17.48% of the portfolio was purchased this quarter.About 4.10% of the portfolio was sold this quarter.This quarter, Lynx1 Capital Management Lp has purchased 18 new stocks and bought additional shares in 5 stocks.Lynx1 Capital Management Lp sold shares of 2 stocks and completely divested from 7 stocks this quarter.Largest Holdings Merus $66,474,364Stoke Therapeutics $57,214,717GH Research $34,012,958C4 Therapeutics $24,669,878Allogene Therapeutics $23,163,160 Largest New Holdings this Quarter Keros Therapeutics $8,611,536 HoldingAllakos $4,390,054 HoldingUPSTREAM BIO INC $3,946,290 HoldingPRECISION BIOSCIENCES INC $2,918,654 HoldingVor Biopharma $707,312 Holding Largest Purchases this Quarter Cullinan Therapeutics 846,965 shares (about $10.32M)Allogene Therapeutics 4,672,349 shares (about $9.95M)Keros Therapeutics 544,001 shares (about $8.61M)GH Research 663,100 shares (about $4.64M)Allakos 3,628,144 shares (about $4.39M) Largest Sales this Quarter Merus 213,025 shares (about $8.96M)C4 Therapeutics 27,783 shares (about $100.02K) Sector Allocation Over TimeMap of 500 Largest Holdings ofLynx1 Capital Management Lp Selling Neutral Buying Latest 13F Holdings and Changes Since Previous Quarterly FilingIssuer NameHoldings ValueApproximate Purchase/SaleChange in SharesShares Held% of PortfolioSectorMRUSMerus$66,474,364$8,957,701 ▼-11.9%1,580,84124.9%MedicalSTOKStoke Therapeutics$57,214,7170.0%5,187,19121.5%MedicalGHRSGH Research$34,012,958$4,641,700 ▲15.8%4,858,99412.8%MedicalCCCCC4 Therapeutics$24,669,878$100,019 ▼-0.4%6,852,7449.2%MedicalALLOAllogene Therapeutics$23,163,160$9,952,103 ▲75.3%10,874,7238.7%MedicalTCRXTScan Therapeutics$16,286,335$403,551 ▲2.5%5,357,3476.1%MedicalCGEMCullinan Therapeutics$15,319,943$10,316,034 ▲206.2%1,257,7955.7%MedicalKROSKeros Therapeutics$8,611,536$8,611,536 ▲New Holding544,0013.2%MedicalPASGPassage Bio$5,249,618$470,692 ▲9.8%9,256,9532.0%MedicalALLKAllakos$4,390,054$4,390,054 ▲New Holding3,628,1441.6%MedicalUPSTREAM BIO INC$3,946,290$3,946,290 ▲New Holding240,0421.5%COMPRECISION BIOSCIENCES INC$2,918,654$2,918,654 ▲New Holding766,0511.1%COM NEWIBIO INC$2,112,5840.0%862,2790.8%CON NEWCRBUCaribou Biosciences$1,081,5010.0%680,1890.4%MedicalVORVor Biopharma$707,312$707,312 ▲New Holding637,2180.3%MedicalCNTACentessa Pharmaceuticals$291,4500.0%17,4000.1%MedicalNEUPHORIA THERAPEUTICS INC$157,115$157,115 ▲New Holding45,8060.1%COMRPTXRepare Therapeutics$103,721$103,721 ▲New Holding79,1760.0%MedicalKODKodiak Sciences$0$707,772 ▼-100.0%00.0%MedicalPIERIS PHARMACEUTICALS INC$0$620,689 ▼-100.0%00.0%COM NEWBNOXBionomics$0$241,471 ▼-100.0%00.0%MedicalKINIKSA PHARMACEUTICALS INTL$0$205,693 ▼-100.0%00.0%ORD SHS CL ATENAX THERAPEUTICS INC$0$51,038 ▼-100.0%00.0%COM NEWIPSCCentury Therapeutics$0$32,538 ▼-100.0%00.0%MedicalVYNEVYNE Therapeutics$0$30,445 ▼-100.0%00.0%MedicalShowing largest 100 holdings. View all holdings. More Institutional Buying and Selling Information SEC Filings and Trading Data SEC Filings 13F Filings Top 13F Buys Top 13F Sells Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
